FAB - Targeting cell senescence to treat chronic wounds

FAB - 靶向细胞衰老治疗慢性伤口

• 批准号: 10025899
• 金额: $ 45.88万
• 依托单位: FIVE ALARM BIO LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10025899
• 关键词: FAB; Targeting; cell; senescence; treat

This project aims to develop a novel approach to healing chronic wounds, a major societal health concern in the elderly and in diabetics. For most healthy people, a cut or scrape heals rapidly on its own, but in diabetics and the elderly wounds can fail to heal, remaining open, needing treatment and causing suffering for months. Five Alarm Bio (FAB) is developing drugs that help the body defend against the chemical damage of aging, damage that is one of the reasons that chronic wounds fail to heal. This project will aim to prove the concept that FAB can use those drugs as a treatment for chronic wounds. FAB will test these new drugs for their ability to keep skin cells healthy for longer, and for their ability to help those cells close up artificial 'wounds' in cell culture in the lab. Success in the project will allow FAB to take the best drugs forward, ultimately to testing them on real patients.

该项目旨在开发一种治疗慢性伤口的新方法，这是老年人和糖尿病患者的主要社会健康问题。对于大多数健康的人来说，割伤或擦伤会自行迅速愈合，但糖尿病患者和老年人的伤口可能无法愈合，保持开放，需要治疗并造成数月的痛苦。Five Alarm Bio（FAB）正在开发药物，帮助身体抵御衰老的化学损伤，这种损伤是慢性伤口无法愈合的原因之一。该项目旨在证明FAB可以使用这些药物治疗慢性伤口的概念。FAB将测试这些新药是否有能力使皮肤细胞保持更长时间的健康，以及是否有能力帮助这些细胞在实验室的细胞培养中闭合人造“伤口”。该项目的成功将使FAB能够将最好的药物推向前进，最终在真实的患者身上进行测试。